Collegium Pharmaceutical Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect eight director nominees to serve one-year terms until the 2027 Annual Meeting.

2. 2

   Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   An advisory (non-binding) vote to approve the compensation of the company's named executive officers as disclosed in the proxy statement.

   More detail

   This proposal asks shareholders to cast a non-binding, advisory vote approving the compensation paid to the company’s named executive officers as described in the proxy statement. Management is seeking this advisory endorsement to validate the design and outcomes of its pay programs — which emphasize a pay-for-performance philosophy, a significant performance-oriented equity component (RSUs and PSUs), and annual cash incentives tied to corporate financial and operational goals — and to demonstrate shareholder support for the compensation committee’s decisions. The proxy describes that long-term equity incentives are split between restricted stock units and performance share units tied to relative TSR metrics, and that annual cash incentives are tied to measurable corporate objectives (e.g., net revenue, Jornay PM® revenue, Adjusted EBITDA, business development, and people & culture goals). The Board recommends a vote FOR because it believes the compensation program aligns executives’ interests with shareholders by emphasizing equity and performance, and because the committee and independent advisor reviewed market data and peer benchmarking when setting pay. The advisory nature of the vote means the board will consider shareholder feedback in future compensation decisions but is not legally bound by the outcome; historical prior say-on-pay results and the company’s disclosure of how it will respond to feedback contextually inform this request. Key governance context includes robust compensation committee oversight, use of an independent compensation consultant, clawback policy, stock ownership guidelines, anti-hedging/anti-pledging policies, and regular peer benchmarking, all of which management cites to justify the program. Investors should weigh the alignment created by performance-based PSUs and the degree to which realized pay reflects company performance (including recent high TSR percentile results for PSU segments and strong 2025 financial performance) against any concerns about the absolute size or mix of pay, severance protections, and the advisory (non-binding) nature of the vote. A FOR vote signals support for the compensation framework and its execution; a substantial dissent could prompt further engagement and potential program adjustments by the compensation committee.

3. 3

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

4. 4

   Transaction of Other Business

   ManagementBoard: FOR

   Consider and vote on any other business properly brought before the Annual Meeting.

   More detail

   This is a standard, catch-all proposal authorizing the meeting to consider and vote on any additional matters that are properly presented at the Annual Meeting but not specifically described in the proxy materials. Management seeks shareholder approval in order to ensure that the meeting can address procedural or emergent items that arise, including ministerial matters, procedural ratifications, or unexpected but proper shareholder proposals introduced at the meeting. The Board recommends a vote FOR as a procedural matter to enable the meeting to function and to allow the Board and management to respond to business that is properly brought before shareholders on short notice. From a governance perspective, this provision does not itself change policy or corporate governance; rather, it preserves shareholders’ ability to transact additional business under applicable law and the company’s governing documents. Investors should not view this item as asking for approval of any specific substantive policy or transaction; any substantive item brought up will still require the specific voting thresholds and disclosures mandated by law and the company’s bylaws. A FOR vote simply authorizes the meeting’s participants and proxies to vote on additional properly presented matters in accordance with their judgment and any instructions provided, and does not bind the Board to any particular action. Because it is standard practice, its primary practical effect is to prevent procedural impediments to addressing legitimate shareholder-initiated or emergent proposals at the Annual Meeting.

Upcoming shareholder meetings at Collegium Pharmaceutical Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Collegium Pharmaceutical Inc 2026 annual meeting?

Collegium Pharmaceutical Inc (COLL) holds its 2026 annual shareholder meeting on Thursday, May 14, 2026.

What is the record date for the Collegium Pharmaceutical Inc 2026 meeting?

The record date for the Collegium Pharmaceutical Inc 2026 meeting is Tuesday, March 31, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Collegium Pharmaceutical Inc's 2026 meeting?

The board is presenting 8 director nominees at the Collegium Pharmaceutical Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Collegium Pharmaceutical Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Collegium Pharmaceutical Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.